- vanya
- 10 Feb, 2003
- New York City
Last year was a sobering one for venture capitalists as investment activity finished at a pace that was the slowest in nearly five years. Will 2003 be better for the VC business?
- kalina
- 03 Feb, 2003
- New York City
Having managed to grow even during an economic slowdown, healthcare and pharma industry top dog Johnson & Johnson, is poised to attain greater heights in the long run.
- vanya
- 27 Jan, 2003
- New York City
Investors have become skittish about software makers, but it might be smart to keep an eye on business intelligence
- kalina
- 20 Jan, 2003
- New York City
The JP Morgan Healthcare meet did little to boost sector stocks, which were already negatively impacted by a slew of bad news. But the market climate is likely to get better soon.
- vanya
- 14 Jan, 2003
- New York City
Nanotechnology has recently emerged as one of the most hotly debated topics around the globe. But, is the
- kalina
- 09 Jan, 2003
- New York City
After a dismal 2001, biotech stocks ended 2002 on a much weaker note. Still, industry fundamentals seem to be improving and some stocks may give patient investors reasons to cheer
- vanya
- 30 Dec, 2002
- New York City
Although the bleak environment of the broader market in 2002 extended to the IPO arena too, there still was good news for investors as new issues outperformed the market as a whole
- kalina
- 26 Dec, 2002
- New York City
Hopes of an imminent biotech-sector recovery were fanned following news that two vital drugs had gained panel recommendations, placing them on the threshold of regulatory approval.
- vanya
- 17 Dec, 2002
- New York City
Online banking failed to live up to its hype, but today, consumers have begun warming up to the idea of banking on the Web. Which players are set to gain from the renewed interest?
- kalina
- 16 Dec, 2002
- New York City
The growing number of cash-hungry biotechs is bound to incite a wave of deals leading to sector consolidation. Biotech leader Gilead Sciences has already benefited from such a deal
- iliana
- 10 Dec, 2002
- New York City
Luxury hotels Starwood and Orient-Express have suffered sorely due to the economic downturn. But, their strong brand presence and margins give them plenty of upside potential.
- kalina
- 04 Dec, 2002
- New York City
The upcoming ASH meeting has been attracting the attention of not only scientists but also investors. This interest may prove to be a boon for biotech stocks in the short run.
- vanya
- 03 Dec, 2002
- New York City
The Sept. 11 attacks and the market downturn have taken their toll on the insurance business, but investors may still find good opportunities in some property and casualty insurers
- kalina
- 26 Nov, 2002
- New York City
Despite the ongoing Federal investigation into the business practices of pharmacy benefit managers (PBMs), hurting sector stocks, their long-term potential remains quite promising.
- iliana
- 24 Nov, 2002
- New York City
Sears may need some help from its customers to achieve a major rebound, and a little more trust from investors to transform once again into a must-have stock.